Development and Commercialisation of a Second Generation Rapid Diagnostic Test (RDT) for Human African Trypanosomiasis (HAT) and other Kinetoplastida

这项研究的总体目标是在之前资助的BBSRC申请的基础上，完成用于检测和诊断寄生虫非洲人类锥虫病（HAT或昏睡病）的新测试的进一步开发和商业化。该疾病威胁着非洲撒哈拉以南地区的4340万人，它是由采采蝇传播的寄生虫感染造成的，开发新的、更可靠和更经济的诊断性生物标志物和分析方法至关重要，特别是对于监测和遏制剩余中至高风险疫源地的传播而言。我们的方法也适用于为诊断、监测和监视由寄生虫病引起的其他疾病而开发新的诊断测试。因此，我们还将把我们的技术应用于开发对其他由锥虫病和着丝体病引起的具有商业和社会重要性的疾病的新的诊断测试。

The overall aim of this research is to complete the further development and commercialisation of new tests for the detection and diagnosis of the parasite Human African Trypanosomiasis (HAT or sleeping sickness), building upon and completing previously funded BBSRC applications. HAT threatens 43.4 million people in the sub-Saharan area of Africa, is the result of infection by parasites transmitted by the tsetse fly, and the development of new, more reliable and economic diagnostic biomarkers and assays is essential, particularly for surveillance and to curb transmission in the remaining moderate to high risk foci. Our approach is also amenable to the development of new diagnostic tests for the diagnosis, monitoring and surveillance of other diseases caused by parasite diseases. We will therefore also apply our technology to the development of new diagnostic tests for other diseases caused by Trypanosomes and Kinetoplastid diseases of commercial and social importance.